-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune checkpoint inhibitors (ICI) may cause life-threatening heart vascular adverse events (CVAE) , which may affect the clinical application of ICI
Immune checkpoint inhibitors (ICI) may cause life-threatening heart vascular adverse events (CVAE) immunity heart blood vessels
Jain et al assessed the incidence and clinical determinants of CVAE using ICI treatment in the actual population, findings recently published in the international journal "ESMO Open" on
"ESMO Open"
Of the 2,687,301 cancer patients diagnosed between 2011 and 2018, 16,574 received ICI anticancer treatment
diagnosis
Cumulative incidence of various adverse cardiovascular events in the two treatment cohorts
Cumulative incidence of various adverse cardiovascular events in the two treatment cohortsThe median ages of patients in the ICI group and non-ICI group were 61 years and 65 years, respectively (p<0.
The highest incidence of CVAE in the ICI group was stroke (4.
Anti-cytotoxic T lymphocyte-associated protein 4 can increase the risk of heart failure and stroke.
Original source:
Original source:Jain P,Gutierrez Bugarin J,Guha A et al.
Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States
in this message
